---
title: "Shanghai Yizhong Pharmaceutical Co., Ltd. (688091.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688091.SH.md"
symbol: "688091.SH"
name: "Shanghai Yizhong Pharmaceutical Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-21T11:47:35.810Z"
locales:
  - [en](https://longbridge.com/en/quote/688091.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688091.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688091.SH.md)
---

# Shanghai Yizhong Pharmaceutical Co., Ltd. (688091.SH)

## Company Overview

Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It also offers paclitaxel polymer nanomicelles for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, gynecological tumors, etc. The company was founded in 2009 and is headquartered in Shanghai, China.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.yizhongpharma.com](https://www.yizhongpharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:13.000Z

**Overall: B (0.33)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 24 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 84.92% |  |
| Net Profit YoY | 949.64% |  |
| P/B Ratio | 8.20 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 11860547634.78 |  |
| Revenue | 324577408.69 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 4.74% | C |
| Profit Margin | 20.94% | A |
| Gross Margin | 85.26% | A |
| Revenue YoY | 84.92% | A |
| Net Profit YoY | 949.64% | A |
| Total Assets YoY | 5.40% | C |
| Net Assets YoY | 1.81% | C |
| Cash Flow Margin | 0.00% | D |
| OCF YoY | 84.92% | A |
| Turnover | 0.22 | D |
| Gearing Ratio | 6.31% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Shanghai Yizhong Pharmaceutical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "84.92%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "949.64%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "8.20",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "11860547634.78",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "324577408.69",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "4.74%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "20.94%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "85.26%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "84.92%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "949.64%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "5.40%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "1.81%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "84.92%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.22",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "6.31%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 173.39 | 154/215 | 1145.04 | 486.07 | 426.39 |
| PB | 8.20 | 207/215 | 8.78 | 7.84 | 6.81 |
| PS (TTM) | 36.65 | 216/215 | 58.57 | 48.04 | 41.19 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688091.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688091.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688091.SH/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**